Max Drawdown (5Y) Chart

View Max Drawdown (5Y) for REGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Max Drawdown (5Y) Chart
Start Trial

Historical Max Drawdown (5Y) Data

View and export this data back to 1991. Start Trial.
Date Value
July 31, 2026 59.69%
June 30, 2026 59.69%
May 31, 2026 59.69%
April 30, 2026 59.69%
March 31, 2026 59.69%
February 28, 2026 59.69%
January 31, 2026 59.69%
December 31, 2025 59.69%
November 30, 2025 59.69%
October 31, 2025 59.69%
September 30, 2025 59.69%
August 31, 2025 59.69%
July 31, 2025 59.69%
June 30, 2025 59.69%
May 31, 2025 59.09%
April 30, 2025 54.48%
March 31, 2025 47.17%
February 28, 2025 44.76%
January 31, 2025 44.00%
December 31, 2024 43.25%
November 30, 2024 43.25%
October 31, 2024 47.49%
September 30, 2024 52.61%
August 31, 2024 53.84%
July 31, 2024 53.84%
Date Value
June 30, 2024 53.84%
May 31, 2024 53.84%
April 30, 2024 53.84%
March 31, 2024 53.84%
February 29, 2024 53.84%
January 31, 2024 53.84%
December 31, 2023 53.84%
November 30, 2023 53.84%
October 31, 2023 53.84%
September 30, 2023 53.84%
August 31, 2023 53.84%
July 31, 2023 53.84%
June 30, 2023 53.84%
May 31, 2023 53.84%
April 30, 2023 53.84%
March 31, 2023 53.84%
February 28, 2023 53.84%
January 31, 2023 53.84%
December 31, 2022 53.84%
November 30, 2022 53.84%
October 31, 2022 53.84%
September 30, 2022 53.84%
August 31, 2022 53.84%
July 31, 2022 53.84%
June 30, 2022 53.84%

Max Drawdown Definition

Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.

Read full definition.

Max Drawdown (5Y) Range, Past 5 Years

View Max Drawdown (5Y) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Max Drawdown (5Y) Benchmarks

View Max Drawdown (5Y) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 58.17%
Gilead Sciences, Inc. 26.58%
AbbVie, Inc. 21.89%
Vertex Pharmaceuticals, Inc. 41.60%
Amgen, Inc. 24.86%